top of page
Post-marketing study of an anti-epileptic drug
In 2012, perampanel was approved and registered in Europe as an anti-epileptic drug. It is used as a complementary treatment in partial epileptic attacks with or without secundary generalization. This observatory cohort study aims to list additional safety risks and to investigate the effects on different subpopulations, such as cardiovascular disorders, psychotic disorders, suicidal behaviour, and impairments of lung, liver and kidney function.
Funding: PZ Duffel and Eisai
Researcher:
bottom of page